{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:32:32Z","timestamp":1793640752627,"version":"4.5.1"},"reference-count":16,"publisher":null,"issue":"1","license":[{"start":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T00:00:00Z","timestamp":1613001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/lib.ossn.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kardiologiia"],"abstract":"<jats:p>\n                    <jats:italic>Aim\u00a0\u00a0\u00a0\u00a0\u00a0<\/jats:italic>\n                    To study the effect of cardioprotective tactics on parameters of left ventricular myocardial perfusion and contractility as per data from single-photon emission computed tomography in oncological patients with signs of anthracycline-induced cardiotoxicity.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Material and methods\u00a0<\/jats:italic>\n                    The study included patients with oncological diseases (n=61) referred to polychemotherapy (PCT). For patients with signs of anthracycline-induced cardiotoxicity, a cardioprotective tactics was used, which included changing the PCT schedule and administering beta-blockers and angiotensin-converting enzyme inhibitors. For all patients at baseline, after the first four PCH courses, after initiation of the cardioprotective tactics and the next four PTC courses, the level of N-terminal pro-brain natriuretic peptide was measured and echocardiography and perfusion single-photon emission computed tomography were performed with assessment of left ventricular (LV) perfusion heterogeneity, systolic and diastolic function.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Results<\/jats:italic>\n                    Following four PTC courses, signs of cardiotoxicity were detected in 13 (21.3\u200a%) patients. On the background of the cardioprotective tactics, a further decrease in LV ejection fraction (EF) by \u20139\u00b12\u200a% (p&lt;0.01) was observed in 4 (30.8\u200a%) patients. In 9 (69.2\u200a%) patients, LV EF increased by 4\u00b12\u200a% (p&lt;0.01). Standard indexes of LV myocardial perfusion did not significantly change. In 7 patients, the cardioprotective tactics was associated with reduced severity of myocardial perfusion disorder, LV\u2206\u03c3\u0422\u2009=\u2009\u20131.37\u00b11.29 (p&lt;0.05), and in 4 patients, with reduced heterogeneity of myocardial perfusion, LV\u2206\u03c3\u041d\u2009= \u20131.20\u00b10.70 (p&lt;0.05).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Conclusion\u00a0\u00a0\u00a0\u00a0\u00a0<\/jats:italic>\n                    The cardioprotective tactics prevents both further disorder of perfusion and decreases in parameters of left ventricular myocardial contractility in patients with anthracycline-induced cardiotoxicity.\n                  <\/jats:p>","DOI":"10.18087\/cardio.2021.1.n1376","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T04:21:35Z","timestamp":1615522895000},"page":"22-27","source":"Crossref","is-referenced-by-count":1,"title":["Effects of Cardioprotective Tactics on the Myocardial Perfusion and Contractile Function of the Left Ventricular Myocardium in Cancer Patients with Evidence of Doxorubicin-Induced Cardiotoxicity"],"prefix":"10.68900","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5663-3005","authenticated-orcid":true,"given":"Yu. A.","family":"Prus","sequence":"first","affiliation":[{"name":"National Medical Research Center of Cardiology, Moscow"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2675-3276","authenticated-orcid":true,"given":"A. A.","family":"Ansheles","sequence":"additional","affiliation":[{"name":"National Medical Research Center of Cardiology, Moscow"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1534-3965","authenticated-orcid":true,"given":"I. V.","family":"Sergienko","sequence":"additional","affiliation":[{"name":"National Medical Research Center of Cardiology, Moscow"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":null,"published-online":{"date-parts":[[2021,2,11]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Valcovici M, Andrica F, Serban C, Dragan S. Cardiotoxicity of anthracycline therapy: current perspectives. Archives of Medical Science. 2016;12(2):428\u201335. DOI: 10.5114\/aoms.2016.59270","DOI":"10.5114\/aoms.2016.59270"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer. 2003;97(11):2869\u201379. DOI: 10.1002\/cncr.11407","DOI":"10.1002\/cncr.11407"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Annals of Oncology. 2020;31(2):171\u201390. DOI: 10.1016\/j.annonc.2019.10.023","DOI":"10.1016\/j.annonc.2019.10.023"},{"key":"ref4","unstructured":"Ansheles A.A., Sergienko I.V., Sergienko V.B. Method of myocardial perfusion initial disturbances and non-uniformity quantitative assessment according to single photon emission computed tomography data. Patent RU 2601098 \u04211. Application: 2015122258\/14 from 2015.06.10. Av. at: https:\/\/yandex.ru\/patents\/doc\/RU2601098C1_20161027.2015."},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Ansheles A.A., Prus Yu.A., Sergienko I.V. Early detection of myocardial perfusion impairments in oncological patients undergoing polychemotherapy. Atherosclerosis and Dyslipidemias. 2020;3(40):60\u2013 8. DOI: 10.34687\/2219-8202.JAD.2020.03.0007","DOI":"10.34687\/2219-8202.JAD.2020.03.0007"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F et al. Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy. Circulation. 2015;131(22):1981\u20138. DOI: 10.1161\/CIRCULATIONAHA.114.013777","DOI":"10.1161\/CIRCULATIONAHA.114.013777"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Cai F, Luis M, Lin X, Wang M, Cai L, Cen C et al. Anthracycline-induced cardiotoxicity in the chemotherapy treatment of breast cancer: Preventive strategies and treatment (Review). Molecular and Clinical Oncology. 2019;11(1):15\u201323. DOI: 10.3892\/mco.2019.1854","DOI":"10.3892\/mco.2019.1854"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Armenian SH, Ehrhardt MJ. Optimizing Cardiovascular Care in Children With Acute Myeloid Leukemia to Improve Cancer-Related Outcomes. Journal of Clinical Oncology. 2019;37(1):1\u20136. DOI: 10.1200\/JCO.18.01421","DOI":"10.1200\/JCO.18.01421"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Asselin BL, Devidas M, Chen L, Franco VI, Pullen J, Borowitz MJ et al. Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children\u2019s Oncology Group Randomized Trial Pediatric Oncology Group 9404. Journal of Clinical Oncology. 2016;34(8):854\u201362. DOI: 10.1200\/JCO.2015.60.8851","DOI":"10.1200\/JCO.2015.60.8851"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Ganatra S, Nohria A, Shah S, Groarke JD, Sharma A, Venesy D et al. Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series. Cardio-Oncology. 2019;5(1):1. DOI: 10.1186\/s40959-019-0036-7","DOI":"10.1186\/s40959-019-0036-7"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. The Cochrane Database of Systematic Reviews. 2011;6:CD003917. DOI: 10.1002\/14651858.CD003917.pub4","DOI":"10.1002\/14651858.CD003917.pub4"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Lipshultz SE, Herman EH. Anthracycline cardiotoxicity: the importance of horizontally integrating pre-clinical and clinical research. Cardiovascular Research. 2018;114(2):205\u20139. DOI: 10.1093\/cvr\/cvx246","DOI":"10.1093\/cvr\/cvx246"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Renu K, Abilash VG, Tirupathi PB, Arunachalam S. Molecular mechanism of doxorubicin-induced cardiomyopathy \u2013 An update. European Journal of Pharmacology. 2018;818:241\u201353. DOI: 10.1016\/j.ejphar.2017.10.043","DOI":"10.1016\/j.ejphar.2017.10.043"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Bansal N, Adams MJ, Ganatra S, Colan SD, Aggarwal S, Steiner R et al. Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors. Cardio-Oncology (London, England). 2019;5:18. DOI: 10.1186\/s40959-019-0054-5","DOI":"10.1186\/s40959-019-0054-5"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Murabito A, Hirsch E, Ghigo A. Mechanisms of Anthracycline-Induced Cardiotoxicity: Is Mitochondrial Dysfunction the Answer? Frontiers in Cardiovascular Medicine. 2020;7:35. DOI: 10.3389\/fcvm.2020.00035","DOI":"10.3389\/fcvm.2020.00035"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Tallaj JA, Franco V, Rayburn BK, Pinderski L, Benza RL, Pamboukian S et al. Response of Doxorubicin-induced Cardiomyopathy to the Current Management Strategy of Heart Failure. The Journal of Heart and Lung Transplantation. 2005;24(12):2196\u2013201. DOI: 10.1016\/j.healun.2004.12.108","DOI":"10.1016\/j.healun.2004.12.108"}],"container-title":["Kardiologiia"],"original-title":[],"link":[{"URL":"https:\/\/lib.ossn.ru\/jour\/article\/viewFile\/1376\/898","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:17:48Z","timestamp":1793639868000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardio.elpub.ru\/jour\/article\/view\/1376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,11]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,2,11]]}},"URL":"https:\/\/doi.org\/10.18087\/cardio.2021.1.n1376","relation":{},"ISSN":["2412-5660","0022-9040"],"issn-type":[{"value":"2412-5660","type":"electronic"},{"value":"0022-9040","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2,11]]}}}